Skip to main content
SpringerLink
Log in

Comorbidities major cost drivers in patients with HIV ± HCV infection

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study received an unconditional grant from Gilead Science srl for the writing of the paper.

Reference

  • Garagiola E, et al. Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice. Health Economics Review : 29 Aug 2020. Available from: URL: https://doi.org/10.1186/s13561-020-00284-x

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Comorbidities major cost drivers in patients with HIV ± HCV infection. PharmacoEcon Outcomes News 861, 10 (2020). https://doi.org/10.1007/s40274-020-7092-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7092-y

Search

Navigation